Results of the SHARP Study: A Randomized, Placebo-Controlled, Double-Blind, Repeated-Measures, Crossover, Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment

Autor: Van Dongen, Hans P.A., Leary, Eileen B., Drake, Christopher, Bogan, Richard, Jaeger, Judith, Rosenberg, Russell, Streicher, Caroline, Tabuteau, Herriot
Zdroj: In Chest
Databáze: ScienceDirect